AFM
GRCE

Anson Funds Management’s Grace Therapeutics GRCE Stock Holding History

Anson Funds Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-14,263
Closed -$527K – 28
2018
Q2 		$527K Buy
+14,263
New +$548K 0.31% 17

Other funds holding GRCE

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Anson Funds Management's GRCE Position: Q3 2018 in Review

Anson Funds Management sold out of Grace Therapeutics (GRCE) in Q3 2018, closing a stake of 14,263 shares — an estimated $527K sold.

Anson Funds Management first reported a position in GRCE in Q2 2018 and held it in 1 quarter. The position peaked at $527K in Q2 2018. 7 funds tracked by Wall St. Rank hold GRCE as of Q3 2018.

  • Anson Funds Management reported no remaining Grace Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Anson Funds Management sold 14,263 Grace Therapeutics shares in Q3 2018, an estimated $527K.
  • Anson Funds Management first reported a position in Grace Therapeutics in Q2 2018 and held it in 1 quarter.
  • Anson Funds Management's Grace Therapeutics position peaked at $527K in Q2 2018.
  • 7 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2018.

Based on Anson Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.